Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy




Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy

CHICAGO, Oct. 31, 2025 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the initiation of a new research and development program leveraging nanotechnology to enhance the effectiveness of phytochemical constituents used in its dietary supplement formulas.

This new initiative builds upon the proprietary know-how developed during the creation of CCX Hydrogel, a breakthrough platform for optimised bioactive delivery. The Company is now expanding its innovation pipeline by developing plant-based extract-loaded phytosomes intended for use in dietary supplements. These nanostructured systems are designed to significantly improve the absorption, stability, and bioactivity of phytochemicals, leading to measurable efficacy improvements.

The approach follows a sustainable, solvent-free process, emphasising environmentally responsible, green formation of phytosomes that are fully suitable for incorporation into nutraceutical applications. This aligns with Cosmos Health’s broader commitment to sustainable innovation, scientific advancement, and responsible manufacturing.

Figure: Stability assessment of the produced phytosomes using Nanoparticle Tracking Analysis.

Greg Siokas, CEO of Cosmos Health, stated: “Our platform represents a promising step toward the development of sustainable, bioactive-enriched food technologies. By combining nanotechnology with advanced phytochemical formulations, we aim to deliver next-generation dietary supplements with validated functional performance and enhanced consumer benefits.”

Dr Panagiotis Zoumpoulakis, Head of Research & Development at Cosmos Health, added: “The integration of nanotechnology into our R&D strategy enables us to explore the full potential of phytochemicals at the molecular level. Through precise nanoscale engineering, we can optimise how these bioactive compounds are absorbed and interact within the body, resulting in superior effectiveness and consistency. This marks a significant advancement in our pursuit of scientifically driven nutraceutical innovation.”

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b1d0d0db-c193-4646-afde-136e62431eb8

Test And Tren Cycle For Muscle Growth – CrazyBulk Lunch Test and Tren Stack (Tren Max) Pills for Bodybuilding, Beginners Dosage, Benefits, Before And After Results




Test And Tren Cycle For Muscle Growth – CrazyBulk Lunch Test and Tren Stack (Tren Max) Pills for Bodybuilding, Beginners Dosage, Benefits, Before And After Results

CrazyBulk Introduce Test and Tren Stack for Bodybuilding, legal Steroids Alternative Pills for Test and Tren Cycle Read Dosage For Beginners, and (Tren Max) Pills Before And After Results

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) —

NEW YORK, Oct 20, 2025, Crazybulk launches Legal Alternatives to the Test and Tren Cycle for Beginners, Bulking, Bodybuilding, and Muscle growth, Cutting. In this article, we will be discussing (Test and Tren Cycle) Before and After Results, Dosage for Beginners of Tren Pills, and Legal Alternatives launched by CrazyBulk. Test And Tren Cycle was first formulated in 1963, and later observations showed that Test And Tren Cycle galvanized ammonium ion production in the body. That in turn accelerates protein synthesis, which eventually results in muscle mass growth.

Test and Tren Cycle is not only useful for a bulking period. It has been shown to reduce fat, assist in training hard, and be just as useful for a cutting period. All in all, Test and Tren Cycle cannot be typecast, as it is a very versatile steroid. Visit Here to Test And Tren Cycle Legal Alternatives Official Website Launch By Crazybulk

The anabolic steroid Alternatives Test and Tren Stack primarily fattens up cattle and livestock. This is to create a financial impact on the livestock owners, who generally exploit it to maximize the money they could make.

Test and Tren Cycle Legal Alternatives Launch By Crazybulk

Usually consumed with stacks, CrazyBulk’s Test and Tren supplements can be very useful for higher muscle growth, rapid recovery, and dynamic workouts all alone. The cycles of consumption can be 10 weeks long, with a dosage that would stay consistent throughout that span.

Depending on what kind of compound you consume, we can determine the outcomes on that basis. As Test and Tren Cycle is a mild substance, the cycle is relatively long and doses are consistent.

The average dose for a beginner would range from 75 to 100 mg. The frequency of consumption would be twice a day, and the cycle would last 8–12 days. Keep in mind that the doses continue throughout the week.

Test and Tren Stack is a great pre-workout compound that ensures an intense workout. As it boosts protein production, it promises a recompositing effect, favoring many areas of your fitness, including bulking and cutting.

Besides, users may choose to stack it with other compounds such as testosterone and even anadrol during the off-season.

Crazybulk launches Best Legal Alternatives to the Test and Tren Cycle For Beginners, As Well As Professional Bodybuilders

For individuals who desire the positive benefits of a test and tren cycle but without the danger of consuming anabolic steroids, there is now a more intelligent option by legal means. These supplements were created to attain such deep effects—naturally and without side effects.

Tren-Max – Formulated for dry muscle gain and fat loss; a Test and Tren Cycle -stimulated compound that drives performance, side effect-free. launches by Crazybulk

Testo-Max – A testosterone-boosting strength booster that works to optimize strength, endurance, and recovery—perfect for natural hormone replacement for intense training sessions. launches by Crazybulk

Visit Here to Test and Tren Cycle Legal Alternatives Tren-Max Official Website.

Is Test and Tren Cycle Legal? Update by Crazy Bulk 

It is legal to consume Test and Tren Cycle in the US. Crazy Bulk launches legal steroid alternatives Test and Tren supplements in various other European states. However, that does not affect its popularity among athletes and bodybuilders.

Fitness enthusiasts feel an inclination towards its utility for a number of reasons. The best of all is its tendency to generate muscle growth and expand musculature. Moreover, its mild temperament makes it ideal to stack with more advanced compounds.

Interestingly, there are countries where one may acquire without a prescription. These include Egypt, the Bahamas, and Puerto Rico.

Test and Tren Cycle Legal Steroid Alternatives Test and Tren Stack Dosage Tips

The following doses are for intermediate- professional bodybuilders who choose to make the most of the Test and Tren Cycle.

The dosing pattern is exclusively favorable for jacked energy, muscle regeneration, and muscle fullness.

Test and Tren Cycle Before and After Result Details by Crazy Bulk

CrazyBulk’s Test and Tren supplements is an enigma. It can either assist someone on their journey towards better health and fitness or riddle them with health problems.

For the interest of this article, we begin with the positives:

• Test and Tren Stack boosts energy levels, which can aid the workout regime and make you more aggressive while working out
• As it synthesizes proteins, it significantly assists in muscle growth. Test and Tren Stack results in dry muscle that seems very aesthetic and pronounced, which is one of its trademarks
• It induces the higher vascularity that bodybuilders seem to seek
• It increases the levels of testosterone, which increases metabolism in the body. The process aims at reducing fat accumulation, especially intramuscular fat, for a defined, toned look

The flip side of the Test and Tren Stack cycle is one of discouraging tidings, with side effects including:

• Hair loss
• In some cases, excessive hair growth occurs
• Acne
• Liver toxicity
• Cardiovascular problems

It is a very effective steroid. Though it starts relatively slowly, after the 2-week mark, the effects start to massively speed up.

Within the first 2 weeks of consumption, the results would be present, but they would focus more on stamina, endurance, and energy levels.

The 2 weeks of using Test and Tren Stack would result in intense, long workouts and a sense of reinvigoration. Users will observe a quantifiable difference in the number of reps they follow.

The increased physical power would show in the increasing number of reps with a sense of ease. This is because stamina and energy levels are at their maximum.

Visit Here to Testo-Max Official Website by Crazybulk Effective Testosterone Booster

How Quickly Does Test and Tren Cycle Work?

For the first 2 weeks, the effects are about potential energy. After the 2-week mark, the results start to show, with an increased reduction in fat and gains in muscle mass.

It would seem as if muscle mass were eating up the fat. But this is because of an increased metabolism that is actually burning up all that fat accumulation.

Considering all that and how fast anabolic steroids usually work, the standards of Test and Tren Cycle for a compound sneered at as a “mild” compound are very consistent compared to much stronger compounds.

The usual time of explosive growth via anabolic steroids is around the 2-week mark, which makes the Test and Tren Stack very consistent.

How many Test and Tren Pills do I need for a Cycle?

For an amateur user, the table in the earlier pages is a dosage recommendation. That was about 150 mg per week, and that would be effective to get the body mass going.

But, in order to maximize Test and Tren Stack use, even a dose of 75 mg would do a lot of good. The conservative doses are to ensure that the side effects are kept at bay. Of course, the higher the dose during the cycle, the greater the risk of side effects!

The cycle would typically last 8–12 weeks. The user should never exceed the dosage and time limits, as it may cause serious harm to the organs. Or even aggravate underlying health problems.

What Does Test and Tren Cycle Do to Your Body?

Test and Tren Stack compounds increase testosterone concentration in the bloodstream, causing the feeling of reinvigoration and a surge of energy. Along with that, it boosts protein synthesis, which in turn galvanizes muscle production and makes those muscles larger.

But the chronological sequence first causes the body to dramatically amp up its metabolism rate. This metabolism starts to use potential energy sources, namely fat, which reduces fat accumulation.

The latter part is the muscle generation that takes place in the second phase of the cycle. This reduction in fat also contributes to higher vascularity, giving the user the typical characteristics of a bodybuilder.

These may appear as hair loss or excessive hair growth, causing cough fits and, most importantly, liver and cardiovascular disorders. Visit Here to the Tren-Max Official Website by Crazybulk

What Can I Expect From Test and Tren Cycle?

To begin with, the expectations should be realistic and based on facts. If not, the user may begin to abuse, believing that the more the better, which is far from the case.

Test and Tren Cycle is not magic. It is an enabler that would assist you in the gym and in your overall bodybuilding journey. Working hard and acting responsibly would be vital to making the most of Test and Tren legal steroid alternatives by CrazyBulk Tren Max.

If the user holds up his or her end of the bargain, then the results are certain. These Test and Tren Cycle results are what we have highlighted at great length earlier.

If not, the results would be far-fetched, and conversely, side effects would start to take effect. One can’t consume or any anabolic compound recreationally and act irresponsibly.

Test and Tren Cycle, legal steroid alternatives, Result Information by CrazyBulk’s Test and Tren supplements

After 8-12 weeks of consumption, you may expect a strength rivaling that of an ox, jacked as can be.

This would only come to fruition if you took the doses after considering your goals and current health condition. Besides, the time you spend training your muscles and making the most of the strength would go a long way.

People may gain a lot of muscle mass in the process. Based on the type of compound within the Test and Tren Cycle family, the body could lose water weight and gain bulging veins.

Test and Tren Cycle Bulking Stack:  legal steroid alternatives, Benefits Details by Crazy Bulk

Famous for their muscle-gaining capabilities, this stacking option is one of the most widely followed combinations in the bodybuilding community. In most cases, it goes into the regimen of powerlifters before a competition or exhibition.

The combination doesn’t increase weight but increases the muscle mass ratio and strength within the body.

Test and Tren Stack, due to its amplification of metabolism, would cause weight loss. But paradoxically, the stack would increase strength and endurance levels.

It’s critical not to exceed the limit of 8 weeks while using these compounds, as it may have detrimental effects. Depending on your bodily predispositions, the dosage should range from 75 mg to 400 mg per week collectively.

Users should be extra responsible while using these compounds. This is because it will show results rather quickly and, if not prepared for in advance, may have adverse effects.

Test and Tren Stack legal alternatives, Benefits Crazy bulk Update

Testosterone and Test and Tren Cycle go decently well with each other. Not only will it enable fat reduction, but it will also increase recovery time and overall strength within the body.

The dosages differ from each other. It is important to note that serial testosterone consumption is limited to powerlifters and poses a risk.

Therefore, for an amateur or intermediate user, a dose of 250–100 mg per week would be more than enough.

Since CrazyBulk’s Test and Tren supplements a mild compounds, a weekly dosage of 75 mg would serve the purpose. Make sure you do not exceed the 300 mg limit, regardless of your goals and circumstances.

Even a liberal use of testosterone can cause estrogen problems in men; hence, be as careful as possible while consuming.

Where To Get CrazyBulk’s Test and Tren supplements?

To make the most of tren pills, one must buy them from the official website.

Conclusion

The manufacturers providelegitimate compounds and discounts to make your bodybuilding hobby work around your budget. Along with that comes a how-to guide to maximize its yield.

Crazy Bulk brand Test and Tren Cycle is often mentioned in bodybuilding forums and online fitness blogs as part of the discussion on strength, muscle building, and body transformation. It’s worth mentioning that most of these are a spin-off from the legacy of classic anabolic steroid cycles with severe health consequences. As opposed to illegal steroids, legal supplements by well-known supplement companies aim at enhancing muscle growth and performance without the inclusion of banned substances.

A typical Test and Tren cycle using anabolic steroids can interfere with hormone balance, raise cardiovascular risk levels, put a strain on the liver, and produce psychological symptoms like mood changes and addiction. For new users, these risks are even more intense, typically resulting in long-term health complications. That’s why most athletes are turning their attentions towards safer, lawful supplement alternatives.

Companies like Crazy Bulk provide legal steroid alternatives that are designed to replicate some of the physical effects of conventional cycles—like aiding lean muscle gains and enhanced recovery—without the negative side effects of actual steroids. The products contain no illegal or controlled compounds, so they are a more moral choice for those dedicated to training.

In summary, whether traditional steroid cycles or legal options, health, safety, and sustainability should always be the top priority. True, enduring results result from effective training, balanced diets, and well-informed choices—not shortcuts that compromise well-being. For those interested in legally improving their performance, examining the Test and Tren Cycle by Crazy Bulk brand as a supplement approach, under professional advice, can provide a safer alternative than illegal performance enhancers.

Manufactured under the Technical Guidance of:

Project name: Crazybulk
244 Madison Avenue,
New York City, NY 10016-2817
Postal code: NY 10016-2817
Media Contact:
Full Name – Neil Bowers
Company website: https://www.crazybulk.com/
email: support@crazybulk.com
+1 888-708-6394
Advertise with us: Info@allprsolution.com

PharmaJet® Signs Distribution Agreement with EVA Pharma to Provide Needle-free Injection Systems to Support Routine Polio Immunization in Egypt




PharmaJet® Signs Distribution Agreement with EVA Pharma to Provide Needle-free Injection Systems to Support Routine Polio Immunization in Egypt

GOLDEN, Colo. and CAIRO, Oct. 31, 2025 (GLOBE NEWSWIRE) — PharmaJet^®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has signed a Distribution Agreement with ATR, an affiliate to EVA Pharma, the leading pharmaceutical company driving healthcare innovation and access across the Middle East and Africa. The agreement, signed in Frankfurt at the CPHI meeting on October 30, 2025, includes provisions for Tropis distribution, technology transfer, and manufacturing.

The aim of the collaboration is to increase needle-free access within Egypt and regionally while broadening Egypt’s manufacturing capabilities. PharmaJet’s Tropis^® intradermal needle-free delivery offers several strategic advantages for Egypt including substantial polio immunization cost savings¹, reduced vaccine hesitancy^2,3, increased coverage³, and the potential for medical technology regional manufacturing. The signing follows the July 2025 Memo of Understanding (MOU) that was signed between PharmaJet, Egypt’s Unified Procurement Agency (UPA) and EVA Pharma, which outlined plans for how UPA could incorporate Tropis into its portfolio.

The introduction of Tropis into immunization programs supports Egypt’s “1000 Golden Days” initiative which was launched to support the health and development of families during the critical period from conception to a child’s second birthday. The collaboration will enable total immunization cost reduction and improved acceptability of polio vaccinations. Longer-term, the Tropis manufacturing and other needle-free product development initiatives may expand the benefits to vaccination against other infectious agents and improved pandemic preparedness.

EVA Pharma is a leading pharmaceutical and medical appliances manufacturing company that has vast experience in manufacturing, registering, marketing, distributing, and promoting pharmaceutical products. “This collaboration puts children first,” said Riad Armanious, CEO of EVA Pharma. “We’re reimagining vaccination through local innovation that improves every child’s experience while empowering healthcare professionals. By localizing manufacturing, we expand access and use existing budgets to reach many more children in Africa sustainably.”

“We are proud to collaborate with ATR and EVA Pharma to localize needle-free manufacturing and delivery,” said Paul LaBarre, Senior Vice President of Business Development for PharmaJet. “This partnership represents a strategic step forward for PharmaJet in the Middle East and Northern Africa region. Working with these innovative teams will accelerate integration of needle-free intradermal vaccine delivery into routine immunization programs in Egypt and beyond.”

Refer to Instructions for Use to ensure safe injections and to review risks.

¹ Data on file
² Soonawala, D et al, Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults, Vaccine, Volume 31, Issue 36, 12 August 2013, Pages 3688-3694
³ Mohan, D et al, Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria’s routine immunization program: An implementation hybrid trial , Vaccines,16 May 2025, 13(5), p.533

Media Contacts:
Nancy Lillie
Nancy.Lillie@PharmaJet.com
1-888-900-4321 Option 3
Marina Faltas
marina.mansour@evapharma.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a68cea50-6f2b-4c9d-80af-cf4a85632192

IntoCell and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC Technologies




IntoCell and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC Technologies

DAEJEON, South Korea and NORTH BETHESDA, Md., Oct. 31, 2025 (GLOBE NEWSWIRE) — IntoCell Inc. (KOSDAQ: 287840), a biotechnology company developing next-generation payload and linker technologies for antibody–drug conjugates (ADCs), and Xcellon Biologics, a U.S.-based contract development and manufacturing organization (CDMO) specializing in ADCs and complex biologics, today announced a strategic collaboration to advance ADC development and manufacturing.

Through this collaboration, IntoCell’s proprietary OHPAS drug-linker platform, which includes Duocarmycin and Nexatecan-based payloads, will be integrated into Xcellon Biologics’ ADC development toolbox. Xcellon will provide bioconjugation, ADC development, and manufacturing services to support biotech and pharmaceutical companies utilizing IntoCell’s technologies as part of their development programs.

The partnership aims to accelerate access to innovative ADC technologies by combining IntoCell’s cutting-edge chemistry platform with Xcellon’s CDMO capabilities and infrastructure in the United States.

“We are pleased to collaborate with Xcellon Biologics, a leading CDMO company,” said Tae Kyo Park, CEO of IntoCell. “We will endeavor to ensure the mutual success of both companies by combining respective areas of expertise. By integrating IntoCell’s proprietary OHPAS linker and payload platforms with Xcellon’s bioconjugation and manufacturing expertise, we aim to provide global innovators with the tools and support necessary to bring differentiated ADC therapies to patients faster.”

“Our vision is to make Xcellon a one-stop shop for the early development of ADCs and complex biologics,” said Abhishake Chhibber, Board Member of Xcellon Biologics. “Partnering with IntoCell strengthens that vision by allowing us to offer our clients access to state-of-the-art linker-payload technologies within a flexible, U.S.-based development framework.”

“This collaboration enhances Xcellon’s ADC toolbox and enables our clients to explore a wider range of payload-linker combinations efficiently,” added Yuk Chiu, Co-Founder & COO of Xcellon Biologics. “By integrating IntoCell’s technologies into our platform, we can accelerate timelines and expand innovation opportunities for next-generation ADC programs.”

The collaboration supports both companies’ missions to enable broader access to high-quality ADC technologies and development capabilities, creating a streamlined path from discovery to manufacturing.

About IntoCell Inc.

IntoCell Inc. is a biotechnology company, KOSDAQ (287840)-listed as of May 2025, based in Daejeon, South Korea, with a focus on developing novel linker and payload technologies for next-generation antibody–drug conjugates (ADCs). The company actively collaborates with partners to develop advanced ADC payload-linker solutions for leading biotechnology and pharmaceutical companies world-wide.
For more information, visit https://intocell.com/en/

About Xcellon Biologics

Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs, is a Maryland-based CDMO specializing in complex biologics, including antibody–drug conjugates (ADCs), bioconjugates, bispecific antibodies, and T-cell engagers.

Xcellon integrates innovative ADC technologies and manufacturing solutions to provide clients with the ability to design and develop ADCs efficiently, cost-effectively, and at speed. Through its flexible and scalable development model, Xcellon supports programs from early discovery through IND readiness—combining technical excellence, reliability, and partnership to advance the next wave of molecular medicines.

For more information, visit www.xcellon.bio.

About Linden Lake Labs

Linden Lake Labs is a life sciences venture creation and development platform based in Maryland. The company builds and scales innovative biotech and biomanufacturing ventures focused on therapeutic discovery, advanced biologics manufacturing, and platform technologies. Linden Lake Labs provides strategic capital, infrastructure, and operational support to its portfolio companies, including Xcellon Biologics, to accelerate the translation of scientific innovation into impactful healthcare solutions.

For more information, visit www.lindenlakelabs.com.

Contact:
Carly Scaduto
carly@thrustsc.com 

Prenetics Bolsters Bitcoin Treasury with Strategic Acquisition of 100 Bitcoin, IM8 Reaches $100M ARR




Prenetics Bolsters Bitcoin Treasury with Strategic Acquisition of 100 Bitcoin, IM8 Reaches $100M ARR

Additional Bitcoin Acquisition Follows Immediately on $44 Million Equity Offering

Company now holds a total of 378 BTC (valued at ~$41 Million)

CHARLOTTE, N.C., Oct. 31, 2025 (GLOBE NEWSWIRE) — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announces the acquisition of 100 Bitcoin, at an average price of $109,594 per Bitcoin. This acquisition demonstrates the Company’s dedication and continued discipline to building its Bitcoin treasury.

Strategic Capital Deployment Following Successful Equity Raise

This Bitcoin acquisition represents the initial deployment of proceeds from Prenetics’ recently completed $44 million equity offering, which closed on October 28, 2025. The significantly oversubscribed offering attracted high-quality strategic investors including Kraken, Exodus, GPTX by Jihan Wu (Founder and CEO of NASDAQ-listed Bitdeer), XtalPi, DL Holdings and World No. 1 tennis champion Aryna Sabalenka, validating the Company’s innovative dual-engine strategy combining health innovation with digital asset treasury management.

“This 100 Bitcoin acquisition demonstrates our immediate execution on the strategic vision we outlined to investors,” said Danny Yeung, Chief Executive Officer of Prenetics. “Given our successful capital raise, our balance sheet is now exceptionally strong with $127 million in total liquidity and zero debt, providing us with substantial runway to execute our growth strategy. With IM8 reaching $100 million in annual recurring revenue in just 11 months—the fastest growth in supplement industry history—our focus is now on accelerating growth for IM8 globally across new markets and product lines. Our dual-engine strategy positions this growth acceleration as our primary driver, while our Bitcoin treasury strategy provides additional long-term value creation. We now have all the capital we need to maintain IM8’s market leadership while building substantial treasury assets for the future.”

Balance Sheet & Liquidity

Following the Bitcoin acquisition and equity raise closing, Prenetics maintains a robust financial position with approximately $127 million in total liquidity ($86 million in cash and $41 million in Bitcoin holdings via 378 BTC). The Company continues its systematic Bitcoin accumulation strategy of 1 Bitcoin per day alongside strategic larger acquisitions during favorable market conditions. This strong balance sheet provides substantial runway for the Company’s dual-engine growth strategy while maintaining zero debt.

IM8

The Company’s IM8 supplement brand continues its record-breaking growth trajectory, having reached $100 million in annual recurring revenue within just 11 months of launch – the fastest growth ever recorded in the global supplements industry. With 420,000 customers and 80% of new orders being subscriptions, IM8 provides a strong cash-generating foundation supporting the Company’s Bitcoin accumulation strategy.

The Company recently released FY2026 Revenue guidance for IM8, expecting revenues of $180 to $200 million.

CEO’s Strategic Vision and Manifesto

The recently released CEO’s comprehensive manifesto, detailing the Company’s ambitious vision, is available at www.prenetics.com/manifesto. The manifesto articulates Yeung’s conviction that traditional corporate treasury strategies are obsolete in an era of currency debasement and digital transformation. It outlines how Prenetics is pioneering the world’s first “health-and-wealth” platform, combining explosive growth in the $700+ billion wellness market with strategic Bitcoin accumulation. The document has garnered significant attention from investors and industry leaders for its bold vision of creating unprecedented shareholder value through this innovative dual-engine approach.

For real-time access to the Company’s Bitcoin holdings, please visit https://prenetics.com/btc

About Prenetics

Prenetics (NASDAQ: PRE) is a leading health sciences company redefining the future of health and longevity through IM8 — its flagship consumer brand co-founded with David Beckham and championed by World No. 1 and four-time Grand Slam winner Aryna Sabalenka — now the fastest-growing supplement brand globally, reaching $100 million in annual recurring revenue within just 11 months of launch — the fastest growth ever recorded in the global history of the supplements industry, even outpacing today’s leading AI startups.

As the first consumer health company to establish a Bitcoin Treasury, Prenetics continues to pioneer at the intersection of health innovation and digital assets — purchasing 1 Bitcoin per day, now totaling 378 BTC as of October 31, 2025.

Investor Relations Contact:

investors@prenetics.com
PRE@mzgroup.us

Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com

CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025




CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025

BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2025, before the market opens on Wednesday, November 12, 2025, and will host a corporate update conference call at 8:30am Eastern Time.

About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath^® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN^® (minocycline), REZZAYO^® (rezafungin), VABOMERE^® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA^® (delafloxacin), and KIMYRSA^® (oritavancin), as well as TOPROL-XL^® (metoprolol succinate).

CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition and Pediatric patient populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Disc Medicine to Participate in Upcoming Investor Conferences




Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at three upcoming investor conferences:

• Guggenheim Second Annual Healthcare Innovation Conference on Monday, November 10^th at 4:30 p.m. ET.
• Stifel 2025 Healthcare Conference on Thursday, November 13^th at 8:40 a.m. ET.
• Jefferies London Healthcare Conference on Wednesday, November 19^th at 2:00 p.m. GMT.

Live webcasts of the fireside chats will be available through the investor relations section of the Company’s website at ir.discmedicine.com and an archived replay will be available after each event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Media Contact

Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com

Investor Relations Contact

Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com

NewGen Enters Into an Innovative Digital Assets Purchase Agreement with White Lion to Acquire up to 600,000 Solana Tokens Valued at Over $110 Million




NewGen Enters Into an Innovative Digital Assets Purchase Agreement with White Lion to Acquire up to 600,000 Solana Tokens Valued at Over $110 Million

BANGKOK, Oct. 31, 2025 (GLOBE NEWSWIRE) — NewGenIvf Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced it has entered a binding term sheet with White Lion Capital LLC (“White Lion”) setting out the principal terms and conditions for a Digital Assets Purchase Agreement (the “Agreement”) with a commitment amount of 600,000 Solana (SOL) tokens.

Pursuant to the Term Sheet, NewGen will have the option, but not the obligation, to sell to White Lion shares of common stock of the Company over an initial 24-month period up to a total amount equivalent to the value of 600,000 Solana tokens. Upon a sale of shares, the Company will be compensated by White Lion in Solana tokens rather than cash. This innovative structure is designed to further the Company’s previously announced Solana treasury strategy, and reaffirms NewGen’s commitment to both the digital assets space as a whole and to Solana as a digital asset specifically.

The transactions contemplated by the Term Sheet are subject to entry into definitive agreements, and are subject to certain conditions, including a registration statement being filed immediately upon execution of the definitive agreements.

Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen commented, “This groundbreaking agreement with White Lion represents another key development in NewGen’s evolution as a forward-thinking, diversified enterprise. By structuring this innovative arrangement to receive Solana tokens rather than traditional cash compensation, we are not only strengthening our digital asset treasury but also demonstrating our unwavering confidence in the future of blockchain technology and decentralized finance. We believe Solana’s robust ecosystem and scalable infrastructure make it an ideal cornerstone for our digital asset strategy, positioning NewGen to capitalize on the tremendous growth opportunities at the intersection of traditional industries and the digital economy.”

Nathan Yee, Managing Partner of White Lion, commented, “We believe this is more than just an investment, it’s a blueprint for the next era of capital formation. By exchanging shares for Solana tokens, we’re witnessing the convergence of blockchain and public markets.”

NewGen launched its digital asset strategy in December 2024, with an initial US$1 million investment to establish a digital asset portfolio. Since then, the Company has embraced digital assets as a core business line, establishing its Solana treasury in June 2025 and advancing innovative real-world asset (RWA) tokenization projects involving real estate and fine art. As of the date of this press release, NewGen has accumulated 13,000 Solana tokens with a total value of approximately US$2.5 million.

About NewGen
NewGenIVF Group is a tech-forward, diversified, multi-jurisdictional high-growth entity capitalizing on emerging opportunities across real estate development, digital asset innovation, and reproductive health solutions. The Company operates through three strategic business divisions that leverage cutting-edge technology and innovative solutions to drive sustainable growth and high ROI for shareholders across multiple global markets. These include “NewGenProperty”, which operates lucrative real estate development projects in the UAE’s Ras Al Khaimah Emirate; “NewGenDigital”, which serves as the Company’s digital assets and DeFi solutions arm; and “NewGenSup”, which focuses on health and longevity products and solutions. NewGen’s legacy business involves providing industry-leading IVF and assisted reproductive treatment services across Asia. With operations spanning multiple jurisdictions and a commitment to innovative, technology-enabled solutions, NewGenIVF Group is uniquely positioned to capitalize on the convergence of real estate, healthcare, and digital asset opportunities in the evolving global economy.

To learn more, visit www.newgenivf.com. The information contained on, or accessible through, NewGen’s website is not incorporated by reference into this press release, and you should not consider it a part of this press release.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are generally identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include but are not limited to: the potential value and benefits of the proposed Digital Assets Purchase Agreement; the Company’s ability to further its Solana treasury strategy and strengthen its digital asset holdings; the Company’s confidence in Solana and blockchain technology; and the potential for growth at the intersection of traditional industries and the digital economy. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s ability to enter into a definitive Digital Assets Purchase Agreement with White Lion on acceptable terms, or at all; the risk that the registration statement required to be filed with the SEC may not become effective or may be delayed; the extreme volatility in the market price of Solana (SOL) and other digital assets, which could significantly impact the value of any potential capital received by the Company and the value of its existing digital asset treasury; the Company’s decision on whether to exercise its option to sell shares, which it is not obligated to do; risks associated with the development, integrity, and maintenance of the Solana blockchain and its broader ecosystem, including potential technical vulnerabilities, security breaches, or network congestion; regulatory risks and uncertainties surrounding digital assets, securities laws, and the treatment of such transactions by regulatory bodies in the jurisdictions where the Company operates; and the Company’s inability to fully implement its broader digital asset strategy or realize the anticipated benefits from its initiatives in the blockchain and digital assets space.

You should carefully consider the foregoing factors and the other risks and uncertainties described in NewGenIvf Group’s Annual Report on Form 20-F and other documents filed or to be filed by NewGenIvf Group with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company and NewGenIvf Group undertake no obligation to update any forward-looking statement, except as required under applicable law.

Investor Relations Contact
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com

Bavarian Nordic Awarded New Procurement Framework Contract by the European Commission to Strengthen Preparedness Against Smallpox and Mpox




Bavarian Nordic Awarded New Procurement Framework Contract by the European Commission to Strengthen Preparedness Against Smallpox and Mpox

• New and larger framework contract with the European Commission’s Health Emergency Preparedness and Response Authority (HERA) replaces previous agreement and provides for up to 8 million doses of smallpox/mpox vaccine over the next four years.
• Additional countries have joined the agreement, now providing access to the vaccine for 20 EU member states and other European countries.

COPENHAGEN, Denmark, October 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the award of a joint procurement contract by the European Commission, through the Health Emergency Preparedness and Response Authority (HERA), enabling the EU, its member states and additional European countries¹ to purchase up to 8 million doses of the Company’s MVA-BN^® smallpox/mpox vaccine.

The two-year agreement, which may be extended for up to additional two years, builds on the previous agreement entered by the parties in 2022, and aims to ensure continuous access to the MVA-BN vaccine throughout Europe. In this extended agreement, the European Commission and 20 countries have confirmed their participation.

Paul Chaplin, President and CEO of Bavarian Nordic said: “We are pleased to extend our collaboration with HERA to facilitate broad access to our smallpox and mpox vaccine across the region. This agreement is a recognition of public health security as part of the resilience that the EU is building to unify against threats on a larger scale, and we are proud to be part of the endeavors to safeguard Europe’s citizens against life-threatening diseases.”

By signing the agreement, approximately 1.1 million doses have already been committed, of which supply of the first 750,000 doses are expected to occur in 2026.

Additionally, the contract contains provisions that allow contracting authorities to procure the vaccine at adjusted price for donations to low- and lower-middle-income countries in response to future outbreaks.

Final contract signature is pending expiry of the statutory 10-day standstill period.

Background
Bavarian Nordic has collaborated with the European Commission’s Health Emergency Preparedness and Response Authority (HERA) since 2022, initially supporting the European Commission’s response to the global mpox outbreak through supply of its MVA-BN vaccine. The framework agreement also allowed the European Commission and European Member States to stockpile MVA-BN as a critical medical countermeasure against a potential reemergence of smallpox.

About the smallpox/mpox vaccine
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore and Mexico (marketed as JYNNEOS^®), Canada (marketed as IMVAMUNE^®), and the EU/EAA and United Kingdom (marketed as IMVANEX^®). Originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general population in individuals considered at risk for smallpox or mpox infection.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:
Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.com
US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600

Contact media:
Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03

Company Announcement no. 35 / 2025

¹ In addition to EU Member states, countries in the European Economic Area (EEA) and the Western Balkan countries are eligible to join the procurement agreement.

Attachment

• Company Announcement no. 35 / 2025

Unprecedented Clinical data from the Landmark BOOSTB4 Trial to be presented at the 15th International Conference on Osteogenesis Imperfecta in Hong Kong




Unprecedented Clinical data from the Landmark BOOSTB4 Trial to be presented at the 15th International Conference on Osteogenesis Imperfecta in Hong Kong

COPENHAGEN, Denmark, Oct. 31, 2025 (GLOBE NEWSWIRE) — BOOST Pharma, a clinical-stage cell biotech company focused on rare skeletal pediatric diseases, is proud to announce that new long-term data from the first-in-class BOOSTB4 stem cell therapy trial has been selected for presentation by BOOST Pharma co-founder Dr. Cecilia Götherström at the prestigious 15th International Conference on Osteogenesis Imperfecta (OI), taking place from October 29-31, 2025, in Hong Kong.

The presentation will provide two-year follow-up data from the landmark BOOSTB4 Phase I/II clinical study. Notably, the results demonstrate that more than 50% of the treated patients experienced zero bone fractures in the second year after last dose (Range 0-5). The previously reported ~70% reduction in fractures during the first year of follow-up was not only sustained but further improved, with an overall reduction of nearly 78% compared to the pre-treatment period. This indicates a durable therapeutic effect of the BT-101 stem cell therapy. These data suggest that BT-101 has the potential to be a disease-modifying cellular therapy, which may effectively prevent new bone fractures in patients with severe OI. Such a treatment could represent a significant advancement for the OI patient community, which currently lacks any approved therapy that modifies the fundamental course of the disease.

“We are excited and honored by the presentation of these groundbreaking results with the global OI and rare disease community in Hong Kong,” said Ingelise Saunders, Chairman of BOOST Pharma. “Demonstrating such a dramatic reduction in fracture rates over a two-year period marks an extraordinary milestone and supports our mission to significantly improve the lives of children born with this severe genetic disorder.”

BOOSTB4 is the world’s first clinical trial to evaluate postnatal and prenatal allogeneic stem cell therapy for OI—also known as brittle bone disease. The therapy, leveraging mesenchymal stem cells with high bone-forming capability, aims to address the genetic cause of OI, moving beyond supportive care and toward lasting, disease-modifying improvement.

About BOOST Pharma ApS

BOOST Pharma is a clinical-stage biopharmaceutical company focused on the development of novel cell therapy treatments. The company is currently developing a first-in-class therapy to treat Osteogenesis Imperfecta, a severe, inherited rare genetic disease leading to significant physical disability. BOOST Pharma is supported by Industrifonden and Karolinska Development, Sweden.

About Osteogenesis Imperfecta

Osteogenesis Imperfecta (OI), also know as Brittle Bone Disease, is a rare and devastating genetic disease, with currently no approved therapies. OI is characterized by fragile bones and reduced bone mass resulting in bones that break easily, loose joints, and weakened teeth. In severe cases, those with OI may experience hundreds of fractures in a lifetime. In addition, people with OI often suffer muscle weakness, early hearing loss, fatigue, curved bones, scoliosis, respiratory problems, and short stature, leading to significant effects on overall health and quality of life. Current treatment of OI is only supportive, focusing on minimizing fractures and maximizing mobility, but to date, there are no FDA or EU approved treatments. OI is estimated to affect 1 in 15,000 people globally.

About the BOOSTB4 Clinical Study

“Boost Brittle Bones Before Birth” (BOOSTB4) is an exploratory, open label, multiple dose, multicenter Phase I/II trial evaluating safety and efficacy of postnatal, or prenatal and postnatal administration, of allogeneic expanded human stem cells for the treatment of severe Osteogenesis Imperfecta (OI) compared with a combination of historical and untreated prospective controls. The aim is to develop a first-in-class cell therapy to reduce the severity of inherited OI in unborn and young children. The study received funding from the European Union’s Horizon 2020 Research and Innovation Program (681045) and from the Swedish Research Council (921-2014-7209) with Karolinska Institutet as study sponsor.

For further information, please contact:

Jonathan Ilicki, Board member
Email: jonathan.ilicki@industrifonden.com